Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Tarsus Pharmaceuticals (TARS) Leases (2020 - 2025)

Tarsus Pharmaceuticals has reported Leases over the past 6 years, most recently at $10.1 million for Q4 2025.

  • Quarterly results put Leases at $10.1 million for Q4 2025, up 1726.09% from a year ago — trailing twelve months through Dec 2025 was $10.1 million (up 1726.09% YoY), and the annual figure for FY2025 was $10.1 million, up 1726.09%.
  • Leases for Q4 2025 was $10.1 million at Tarsus Pharmaceuticals, down from $10.2 million in the prior quarter.
  • Over the last five years, Leases for TARS hit a ceiling of $10.2 million in Q3 2025 and a floor of $229000.0 in Q2 2025.
  • Median Leases over the past 5 years was $1.0 million (2021), compared with a mean of $2.0 million.
  • Peak annual rise in Leases hit 1726.09% in 2025, while the deepest fall reached 88.37% in 2025.
  • Tarsus Pharmaceuticals' Leases stood at $1.1 million in 2021, then plummeted by 46.46% to $575000.0 in 2022, then skyrocketed by 226.96% to $1.9 million in 2023, then crashed by 70.64% to $552000.0 in 2024, then soared by 1726.09% to $10.1 million in 2025.
  • The last three reported values for Leases were $10.1 million (Q4 2025), $10.2 million (Q3 2025), and $229000.0 (Q2 2025) per Business Quant data.